➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
AstraZeneca
Johnson and Johnson
Merck
Boehringer Ingelheim

Last Updated: September 21, 2021

DrugPatentWatch Database Preview

Claims for Patent: 9,549,899


Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,549,899
Title:Abuse deterrent pharmaceutical compositions for controlled release
Abstract: The present disclosure relates to pharmaceutical compositions that are abuse resistant and may also provide controlled release. The present disclosure also relates to the use of pharmaceutical compositions in the treatment of pain.
Inventor(s): Tygesen; Peter Holm (Vaerlose, DK), Lindhardt; Karsten (Haslev, DK), Olsen; Martin Rex (Holbaek, DK), Fischer; Gina Engslev (Vaerlose, DK), Overgard; Jan Martin (Frederikssund, DK), Boye; Georg (Hedehusene, DK), Skak; Nikolaj (Virum, DK), Elhauge; Torben (Copenhagen K, DK)
Assignee: EGALET LTD. (London, GB)
Application Number:13/933,053
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,549,899
Patent Claims: 1. An abuse-deterrent tablet formulated for oral administration of an opioid, the tablet consisting of a tablet composition and, optionally, a cosmetic coat, wherein: the tablet composition consists of: (a) about 1-70% w/w of the opioid; and (b) about 30-98% w/w of a polyethylene oxide (PEO) selected from the group consisting of (i) a single PEO having an average molecular weight of from about 400,000 daltons to about 900,000 daltons and (ii) two or more PEOs having a combined average molecular weight of from about 400,000 daltons to about 900,000 daltons and, optionally, (c) a stabilizer selected from one or more of tripropylene glycol (TPG), tocopherol polyethylene glycol succinate (TPGS), butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), t-butyl hydroquinone, calcium ascorbate, gallic acid, hydroquinone, maltol, octyl gallate, sodium bisulfite, sodium metabisulfite, tocopherol, citric acid, tartaric acid, ascorbic acid, phosphite, erythorbic acid, etidronic acid, hypophosphorous acid, nordihydroguaiaretic acid, propionic acid, dodecyl gallate, octyl gallate, 1,3,5-trihydroxybenzene, calcium ascorbate, sodium ascorbate, sodium bisulphite, sodium metabisulfite, sodium sulfite, potassium bisulphite, potassium metabisulphite), dilauryl thiodipropionate, dimyristyl thiodipropionate, distearyl thiodipropionate, tocopherol, D-.alpha.-tocopherol, d,l-.alpha.-tocopherol, tocopheryl acetate, d-.alpha.-tocopheryl acetate, d,l-.alpha.-tocopheryl acetate, sorbitol glyceryl tricitrate, and sucrose octaacetate, the cosmetic coat, when present, covers at least a portion of the tablet composition, and dissolves within 30 minutes after contact with aqueous media, wherein the tablet composition does not provide immediate release of the opioid even after being subjected to physical tampering selected from crushing, grinding, grating, cutting, or crisping, and wherein the tablet composition exhibits a viscosity of at least 170 mPas when measured by Viscosity Test #2, or a viscosity of at least 46 Pas when measured by Viscosity Test #1.

2. The abuse deterrent tablet of claim 1, wherein the tablet composition is resistant to physical tampering such that after being subjected to grating using a grater with a stainless steel blade for 1 1/2 minutes the grated composition does not exhibit immediate release of the opioid by releasing at least 80% w/w of the opioid within 30 minutes, when subjected to dissolution testing according to USP 35, NF 30, (711), Apparatus 2, in 900mL of dilute hydrochloric acid dissolution medium and a paddle rotation speed of 75 rpm.

3. The abuse deterrent tablet of claim 1, wherein the tablet composition is resistant to physical tampering such that after being subjected to grinding in a coffee grinder with stainless steel blades at 30,000-50,000 rpm for 15 seconds at least 90 wt % of the composition exhibits a particle size of larger than about 1,050 .mu.m.

4. The abuse deterrent tablet of claim 1, wherein the tablet composition is resistant to physical tampering such that after being subjected to grinding in a coffee grinder with stainless steel blades at 30,000-50,000 rpm for 15 seconds the grinded composition does not exhibit immediate release of the opioid by releasing at least 80% w/w of the opioid within 30 minutes, when subjected to dissolution testing according to USP 35, NF 30, (711), Apparatus 2, in 900 mL of dilute hydrochloric acid dissolution medium and a paddle rotation speed of 75 rpm.

5. The abuse deterrent tablet of claim 1, wherein the opioid is selected from the group consisting of buprenorphine, codeine, dextromoramide, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, morphine, pentazocine, oxycodeine, oxycodone, oxymorphone, norhydrocodone, noroxycodone, morphine-6-glucuronode, tramadol, tapentadol, dihydromorphine, and pharmaceutically acceptable salts thereof.

6. The abuse deterrent tablet of claim 1, wherein the opioid is selected from the group consisting of morphine and pharmaceutically acceptable salts thereof.

7. The abuse deterrent tablet of claim 1, wherein the tablet composition exhibits a release rate of opioid in phosphate buffered saline with 40% v/v ethanol that is equal to or lower than the release rate of opioid in phosphate buffered saline.

8. The abuse deterrent tablet of claim 1, wherein the tablet yields a non-snortable composition when subjected to physical tampering selected from crushing, hammering, grinding, grating, and cutting.

9. The abuse deterrent tablet of claim 1, wherein the average molecular weight of the PEO included in the tablet composition is from about 400,000 to about 600,000 daltons.

10. The abuse deterrent tablet of claim 1, wherein the average molecular weight of the PEO included in the tablet composition is about 400,000 daltons.

11. The abuse deterrent tablet of claim 1, wherein the tablet composition comprises two or more active drug substances.

12. A method for treating an individual suffering from moderate to severe pain, the method comprising administering to the individual an abuse-deterrent tablet according to claim 1.

13. An abuse-deterrent tablet formulated for oral administration of an opioid, the tablet consisting of a tablet composition and, optionally, a cosmetic coat, wherein: the tablet composition consists of: (a) about 1-70% w/w of the opioid; and (b) about 30-98% w/w of a polyethylene oxide (PEO) selected from the group consisting of (i) a single PEO having an average molecular weight of from about 400,000 daltons to about 900,000 daltons and (ii) two or more PEOs having a combined average molecular weight of from about 400,000 daltons to about 900,000 daltons and, optionally, (c) a stabilizer selected from one or more of tripropylene glycol (TPG), tocopherol polyethylene glycol succinate (TPGS), butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), t-butyl hydroquinone, calcium ascorbate, gallic acid, hydroquinone, maltol, octyl gallate, sodium bisulfite, sodium metabisulfite, tocopherol, citric acid, tartaric acid, ascorbic acid, phosphite, erythorbic acid, etidronic acid, hypophosphorous acid, nordihydroguaiaretic acid, propionic acid, dodecyl gallate, octyl gallate, 1,3,5-trihydroxybenzene, calcium ascorbate, sodium ascorbate, sodium bisulphite, sodium metabisulfite, sodium sulfite, potassium bisulphite, potassium metabisulphite), dilauryl thiodipropionate, dimyristyl thiodipropionate, distearyl thiodipropionate, tocopherol, D-.alpha.-tocopherol, d,l-.alpha.-tocopherol, tocopheryl acetate, d-.alpha.-tocopheryl acetate, d,l-.alpha.-tocopheryl acetate, sorbitol glyceryl tricitrate, and sucrose octaacetate, the cosmetic coat, when present, covers at least a portion of the tablet composition, and dissolves within 30 minutes after contact with aqueous media, wherein the tablet composition is resistant to physical tampering such that after being subjected to grating using a grater with a stainless steel blade for 1 1/2 minutes the grated composition does not exhibit immediate release of the opioid by releasing at least 80% w/w of the opioid within 30 minutes, when subjected to dissolution testing according to USP 35, NF 30, (711), Apparatus 2, in 900 mL of dilute hydrochloric acid dissolution medium and a paddle rotation speed of 75 rpm.

14. The abuse deterrent tablet of claim 13, wherein the opioid is selected from the group consisting of buprenorphine, codeine, dextromoramide, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, morphine, pentazocine, oxycodeine, oxycodone, oxymorphone, norhydrocodone, noroxycodone, morphine-6-glucuronode, tramadol, tapentadol, dihydromorphine, and pharmaceutically acceptable salts thereof.

15. The abuse deterrent tablet of claim 13, wherein the opioid is selected from the group consisting of morphine and pharmaceutically acceptable salts thereof.

16. The abuse deterrent tablet of claim 13, wherein the tablet composition exhibits a release rate of opioid in phosphate buffered saline with 40% v/v ethanol that is equal to or lower than the release rate of opioid in phosphate buffered saline.

17. The abuse deterrent tablet of claim 13, wherein the tablet yields a non-snortable composition when subjected to physical tampering selected from crushing, hammering, grinding, grating, and cutting.

18. The abuse deterrent tablet of claim 13, wherein the average molecular weight of the PEO included in the tablet composition is from about 400,000 to about 600,000 daltons.

19. The abuse deterrent tablet of claim 13, wherein the average molecular weight of the PEO included in the tablet composition is about 400,000 daltons.

20. A method for treating an individual suffering from moderate to severe pain, the method comprising administering to the individual an abuse-deterrent tablet according to claim 13.

21. An abuse-deterrent tablet formulated for oral administration of an opioid, the tablet consisting of a tablet composition and, optionally, a cosmetic coat, wherein: the tablet composition consists of: (a) about 1-70% w/w of the opioid; and (b) about 30-98% w/w of a polyethylene oxide (PEO) selected from the group consisting of (i) a single PEO having an average molecular weight of from about 400,000 daltons to about 900,000 daltons and (ii) two or more PEOs having a combined average molecular weight of from about 400,000 daltons to about 900,000 daltons and, optionally, (c) a stabilizer selected from one or more of tripropylene glycol (TPG), tocopherol polyethylene glycol succinate (TPGS), butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), t-butyl hydroquinone, calcium ascorbate, gallic acid, hydroquinone, maltol, octyl gallate, sodium bisulfite, sodium metabisulfite, tocopherol, citric acid, tartaric acid, ascorbic acid, phosphite, erythorbic acid, etidronic acid, hypophosphorous acid, nordihydroguaiaretic acid, propionic acid, dodecyl gallate, octyl gallate, 1,3,5-trihydroxybenzene, calcium ascorbate, sodium ascorbate, sodium bisulphite, sodium metabisulfite, sodium sulfite, potassium bisulphite, potassium metabisulphite), dilauryl thiodipropionate, dimyristyl thiodipropionate, distearyl thiodipropionate, tocopherol, D-.alpha.-tocopherol, d,l-.alpha.-tocopherol, tocopheryl acetate, d-.alpha.-tocopheryl acetate, d,l-.alpha.-tocopheryl acetate, sorbitol glyceryl tricitrate, and sucrose octaacetate, the cosmetic coat, when present, covers at least a portion of the tablet composition, and dissolves within 30 minutes after contact with aqueous media, wherein the tablet composition is resistant to physical tampering such that after being subjected grinding in a coffee grinder with stainless steel blades at 30,000-50,000 rpm for 15 seconds the grinded composition does not exhibit immediate release of the opioid by releasing at least 80% w/w of the opioid within 30 minutes, when subjected to dissolution testing according to USP 35, NF 30, (711), Apparatus 2, in 900 mL of dilute hydrochloric acid dissolution medium and a paddle rotation speed of 75 rpm.

22. The abuse deterrent tablet of claim 21, wherein the tablet composition is resistant to physical tampering such that after being subjected to grinding in a coffee grinder with stainless steel blades at 30,000-50,000 rpm for 15 seconds at least 90 wt % of the composition exhibits a particle size of larger than about 1,050 .mu.m.

23. The abuse deterrent tablet of claim 21, wherein the opioid is selected from the group consisting of buprenorphine, codeine, dextromoramide, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, morphine, pentazocine, oxycodeine, oxycodone, oxymorphone, norhydrocodone, noroxycodone, morphine-6-glucuronode, tramadol, tapentadol, dihydromorphine, and pharmaceutically acceptable salts thereof.

24. The abuse deterrent tablet of claim 21, wherein the opioid is selected from the group consisting of morphine and pharmaceutically acceptable salts thereof.

25. The abuse deterrent tablet of claim 21, wherein the tablet composition exhibits a release rate of opioid in phosphate buffered saline with 40% v/v ethanol that is equal to or lower than the release rate of opioid in phosphate buffered saline.

26. The abuse deterrent tablet of claim 21, wherein the tablet yields a non-snortable composition when subjected to physical tampering selected from crushing, hammering, grinding, grating, and cutting.

27. The abuse deterrent tablet of claim 21, wherein the average molecular weight of the PEO included in the tablet composition is from about 400,000 to about 600,000 daltons.

28. The abuse deterrent tablet of claim 21, wherein the average molecular weight of the PEO included in the tablet composition is about 400,000 daltons.

29. A method for treating an individual suffering from moderate to severe pain, the method comprising administering to the individual an abuse-deterrent tablet according to claim 21.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
Johnson and Johnson
Merck
Boehringer Ingelheim
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.